Monday 28th February 2022
Melito announced the signing of a special license agreement with the Institute of specialty French biotechnology for research and development of next-generation antiviral treatments, today, Pasteur Institute for the development of a new class of antiviral treatment.
This license agreement allows Melito therapists to access a state-of-the-art technology platform, which allows defective viral genes or statute (defective viral genes), with an early virus copies mutations or eliminated, changing its performance and its pathogens characteristics.
Developed by the Marco vignette, the head of the viral population and pastogenesis unit, this next-generation technology platform enables one to identify bipedalism with very specific genetic modifications, inhibiting their pathogenic effect, for the purpose of the strong ability to compete with the original virus for replication in guest cells.
Therefore, these non-grafted viral scenes and, ultimately, for partial or total resistance for the development of viral treatments can lead to potential complications.
The license agreement with the institution Pasteur allows Melito to produce and develop therapeutics, an infectious agent that spreads together with a dividend from Marco wynuja and Zika virus (1.5 million cases at the time of the last epidemic in Brazil in 2015) and it can cause extremely significant nerve damage for squeeze with infection of the pregnant woman; and in chikungunya, which causes infected disease diagnosis of millions of people since 2005…